Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$242.45 USD

242.45
459,253

-6.56 (-2.63%)

Updated Sep 25, 2024 04:00 PM ET

After-Market: $242.74 +0.29 (0.12%) 5:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (172 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Factors Setting Stage for CVS Health's (CVS) Q1 Earnings

CVS Health (CVS) expects robust 2018 PBM selling season and strong Pharmacy Services segment to drive earnings in Q1.

    Can ResMed (RMD) Repeat Stable Device Growth in Q3 Earnings?

    ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.

      Quest Diagnostics (DGX) Q1 Earnings Meet, Guidance Intact

      Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.

        Can Steady Overall Growth Drive Align's (ALGN) Q1 Earnings?

        Align Technology (ALGN) is likely to gain from strength in the Invisalign space as well as Scanner and Service business in Q1.

          Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained

          Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.

            Henry Schein Ties Up With Internet Brands to Boost Dental Arm

            Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.

              Zacks.com featured highlights include: Amazon.com, Align, Axon Enterprise, Antero and Jones Lang

              Zacks.com featured highlights include: Amazon.com, Align, Axon Enterprise, Antero and Jones Lang

                Company News For April 6, 2018

                Companies In The News are: MON,BAYN,GMS,CYOU,ALGN

                  Sanghamitra Saha headshot

                  Get Earnings Surprise From 5 Top Stocks & Beat Market Blues

                  These top-ranked stocks are likely to beat on the bottom line in their next releases.

                    Align Unveils Vivera Retainers for Deep Bite Correction

                    Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.

                      Align Technology Broadens Invisalign Suite, Extends Reach

                      Align Technology (ALGN) leaves no stone unturned to boost the Invisalign product portfolio and strengthen its hold in the high-potential invisible orthodontics market.

                        Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan

                        Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the Molecular Diagnostics portfolio.

                          Ensign Group Boosts Arizona Base With Real Estate Buyout

                          Ensign Group's (ENSG) inclination toward inorganic growth leads to numerous acquisitions, significantly favoring the company's top line.

                            Boston Scientific to Acquire Securus Medical, Boost EP Unit

                            Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

                              Gargi Seth headshot

                              Dental Implant & Prosthetic Boom Puts Spotlight on 3 Stocks

                              The dental market has outperformed the broader market in last ten years on the back of demand from both teenagers and adults.

                                Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?

                                Walgreens Boots' (WBA) increase in sales at the Retail Pharmacy International segment, on account of the company's strategic tie-ups, along with strength in other businesses buoy optimism.

                                  Align Technology Banks on Global Growth, Competition Rife

                                  We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.

                                    Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales

                                    Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.

                                      Mark Vickery headshot

                                      Post-Market Q4 Earnings Parade: SFLY, ALGN & More

                                      Following today's closing bell, we see fresh quarterly earnings results from a host of new companies.

                                        Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?

                                        Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.

                                          Align Rides on Balanced Segmental Growth Amid Stiff Contest

                                          Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.

                                            Universal Health Grows Inorganically, Rising Costs a Drag

                                            Universal Health's (UHS) top line grows on solid Acute Care and Behavioral Health platforms. Nevertheless, surging level of debt bothers.

                                              Zimmer Biomet Strong on Positive Data From PROGRESS II Study

                                              Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.

                                                Here's Why You Should Invest in Masimo (MASI) Right Now

                                                Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.

                                                  Haemonetics Banks on Hospital Business, Competition Rife

                                                  For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.